Andrea Akinbola

Andrea Akinbola is an associate in Goodwin’s Business Law department. Andrea advises public and private life sciences and technology companies in connection with mergers and acquisitions and other complex and strategic transactions. Andrea also advises clients on corporate governance and securities law matters. Andrea joined Goodwin in 2022. 

Andrea’s recent transactions include:

• Ouro Medicines in its acquisition by Gilead Sciences up to $2.375 billion
• Orna Therapeutics in its acquisition by Eli Lilly for up to $2.4 billion
• Avadel in its sale to Alkermes plc for up to $2.4 billion
• Esperion in its $75 million underwritten public offering
• Olo Inc. in its agreement to be acquired by Thoma Bravo for approximately $2 billion
• Inozyme Pharma in its $270 million acquisition by BioMarin
• 2seventy Bio in its acquisition by Bristol Myers Squibb for approximately $286 million
• Aclarion in the $4.7 million closing of its registered direct offering of common stock
• Enfusion in its $1.5 billion acquisition by Clearwater Analytics
• Novo Holdings in its $16.5 billion acquisition of Catalent
• AlloVir in its merger agreement to combine with Kalaris Therapeutics
• SciAps in its acquisition by Spectris PLC for up to $260 million
• HI-Bio in its acquisition by Biogen for up to $1.8 billion
• Underwriters in American Healthcare REIT’s $772.8 million IPO
• Q32 Bio Inc. in its merger agreement to combine with Homology Medicines
• Thoma Bravo in its acquisition of NextGen Healthcare
• Orchard Therapeutics in its sale to Kyowa Kirin for up to $447 million
• Korro Bio in its definitive merger agreement with Frequency Therapeutics